Paraneoplastic neurological syndrome: growing spectrum and relevance.
Immune checkpoint inhibitors
PNS criteria
Paraneoplastic neurological syndromes
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
16
03
2022
accepted:
15
04
2022
pubmed:
24
4
2022
medline:
24
5
2022
entrez:
23
4
2022
Statut:
ppublish
Résumé
Paraneoplastic neurological syndromes (PNSs) are group of disorders affecting one or multiple parts of the neuroaxis associated with underlying tumors. An antibody or autoantigen-specific cell-mediated immune response against neural antigen expressed in the tumor is the potential etiology for these rare but refractory disorders. In recent years, wide variety of neurological presentations and autoantibodies has been associated with paraneoplastic autoimmunity, leading to formulation of an updated expert consensus PNS diagnostic criteria. Recognition of these phenotypes and use of serological biomarkers may aid neurologists in early diagnosis of PNS cases encountered in the inpatient or outpatient practice. In this review article, we provide an overview of various clinical, radiological, and immunopathological characteristics of PNS. Furthermore, we discuss the updated PNS criteria and increasing recognition of neurological presentations resembling the PNS among patients receiving immune checkpoint inhibitors.
Identifiants
pubmed: 35460452
doi: 10.1007/s10072-022-06083-y
pii: 10.1007/s10072-022-06083-y
doi:
Substances chimiques
Autoantibodies
0
Autoantigens
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3583-3594Informations de copyright
© 2022. Fondazione Società Italiana di Neurologia.
Références
Giometto B, Grisold W, Vitaliani R et al (2010) Paraneoplastic neurologic syndrome in the PNS euronetwork database: a European study from 20 centers. Arch Neurol 67:330–5. https://doi.org/10.1001/archneurol.2009.341
doi: 10.1001/archneurol.2009.341
pubmed: 20212230
Schulz P, Prüss H (2015) Hirnsymptome bei Carcinomatose "-Hermann Oppenheim and an early description of a paraneoplastic neurological syndrome. J Hist Neurosci 24:371–7. https://doi.org/10.1080/0964704X.2015.1021120
doi: 10.1080/0964704X.2015.1021120
pubmed: 25802985
pmcid: 4673590
Wilkinson PC, Zeromski J (1965) Immunofluorescent detection of antibodies against neurones in sensory carcinomatous neuropathy. Brain 88:529–83. https://doi.org/10.1093/brain/88.3.529
doi: 10.1093/brain/88.3.529
pubmed: 5318822
Darnell RB, Posner JB (2003) Paraneoplastic syndromes involving the nervous system. N Engl J Med 349:1543–54. https://doi.org/10.1056/nejmra023009
doi: 10.1056/nejmra023009
pubmed: 14561798
Vogrig A, Gigli GL, Segatti S et al (2019) (2019) Epidemiology of paraneoplastic neurological syndromes: a population-based study. J Neurol 2671(267):26–35. https://doi.org/10.1007/S00415-019-09544-1
doi: 10.1007/S00415-019-09544-1
Hébert J, Riche B, Vogrig A et al (2020) Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France. Neurol Neuroimmunol neuroinflammation 7:e883. https://doi.org/10.1212/NXI.0000000000000883
doi: 10.1212/NXI.0000000000000883
Shah S, Flanagan EP, Paul P et al (2022) Population-based epidemiology study of paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflammation 9:e1124. https://doi.org/10.1212/NXI.0000000000001124
doi: 10.1212/NXI.0000000000001124
Joseph CG, Darrah E, Shah AA, et al (2014) Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science (80- ) 343:. https://doi.org/10.1126/science.1246886
Villadangos JA (2007 Jul) Schnorrer P (2007) Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol 7(7):543–555. https://doi.org/10.1038/nri2103
doi: 10.1038/nri2103
pubmed: 17589544
Darnell RB (1996) Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Proc. Natl. Acad. Sci. U. S. A. May 14;93(10):4529–36. https://doi.org/10.1073/pnas.93.10.4529 .
Ridge JP, Di Rosa F, Matzinger P (1998) A conditioned dendritic cell can be a temporal bridge between a CD4 + T-helper and a T-killer cell. Nature 393:474–8. https://doi.org/10.1038/30989
doi: 10.1038/30989
pubmed: 9624003
Zekeridou A, Lennon VA (2019) Neurologic autoimmunity in the era of checkpoint inhibitor cancer immunotherapy. Mayo Clin Proc 94(9):1865–1878. https://doi.org/10.1016/j.mayocp.2019.02.003
doi: 10.1016/j.mayocp.2019.02.003
pubmed: 31358366
Graus F, Vogrig A, Muñiz-Castrillo S, et al (2021) Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol - Neuroimmunol Neuroinflammation 8. https://doi.org/10.1212/NXI.0000000000001014
Henson RA, Hoffman HL, Urich H (1965) Encephalomyelitis with carcinoma. Brain 88:449–464. https://doi.org/10.1093/BRAIN/88.3.449
doi: 10.1093/BRAIN/88.3.449
pubmed: 5890519
Graus F, Keime-Guibert F, Reñe R, et al (2001) Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. 124(Pt 6):1138–48. https://doi.org/10.1093/brain/124.6.1138 .
Graus F, Keime-Guibert F, Reñe R et al (2001) Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 124:1138–1148. https://doi.org/10.1093/BRAIN/124.6.1138
doi: 10.1093/BRAIN/124.6.1138
pubmed: 11353730
Yu Z, Kryzer TJ, Griesmann GE et al (2001) CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 49:146–54. https://doi.org/10.1002/1531-8249(20010201)49:2%3c146::AID-ANA34%3e3.0.CO;2-E
doi: 10.1002/1531-8249(20010201)49:2<146::AID-ANA34>3.0.CO;2-E
pubmed: 11220734
Dubey D, Lennon VA, Gadoth A et al (2018) Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. Neurology 90:e103–e110. https://doi.org/10.1212/WNL.0000000000004803
doi: 10.1212/WNL.0000000000004803
pubmed: 29222126
Gultekin SH, Rosenfeld MR, Voltz R et al (2000) Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 123:1481–94. https://doi.org/10.1093/brain/123.7.1481
doi: 10.1093/brain/123.7.1481
pubmed: 10869059
Dalmau J, Graus F, Villarejo A et al (2004) Clinical analysis of anti-Ma2-associated encephalitis. Brain 127:1831–44. https://doi.org/10.1093/brain/awh203
doi: 10.1093/brain/awh203
pubmed: 15215214
Peterson K, Rosenblum MK, Kotanides H, Posner JB (1992) Paraneoplastic cerebellar degeneration: I.A clinical analysis of 55 anti–Yo antibody–positive patients. Neurology 42:. https://doi.org/10.1212/wnl.42.10.1931
Dubey D, Kryzer T, Guo Y et al (2021) Leucine Zipper 4 autoantibody: a novel germ cell tumor and paraneoplastic biomarker. Ann Neurol 89:1001–1010. https://doi.org/10.1002/ANA.26050
doi: 10.1002/ANA.26050
pubmed: 33583072
Vogrig A, Péricart S, Pinto A-L et al (2021) Immunopathogenesis and proposed clinical score for identifying Kelch-like protein-11 encephalitis. Brain Commun 3:fcab185. https://doi.org/10.1093/braincomms/fcab185
doi: 10.1093/braincomms/fcab185
pubmed: 34557666
pmcid: 8453430
De Graaff E, Maat P, Hulsenboom E et al (2012) Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol 71:815–24. https://doi.org/10.1002/ana.23550
doi: 10.1002/ana.23550
pubmed: 22447725
Ruiz-García R, Martínez-Hernández E, Joubert B et al (2020) Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2. Neurol - Neuroimmunol Neuroinflammation 7:658. https://doi.org/10.1212/NXI.0000000000000658
doi: 10.1212/NXI.0000000000000658
Valencia-Sanchez C, Knight AM, Hammami MB et al (2022) Characterisation of TRIM46 autoantibody-associated paraneoplastic neurological syndrome. J Neurol Neurosurg Psychiatry 93:196–200. https://doi.org/10.1136/JNNP-2021-326656
doi: 10.1136/JNNP-2021-326656
pubmed: 34921120
Do LD, Gupton SL, Tanji K et al (2019) TRIM9 and TRIM67 are new targets in paraneoplastic cerebellar degeneration HHS Public Access. Cerebellum 18:245–254. https://doi.org/10.1007/s12311-018-0987-5
doi: 10.1007/s12311-018-0987-5
pubmed: 30350014
pmcid: 6445697
Gorman MP (2010) Update on diagnosis, treatment, and prognosis in opsoclonus-myoclonus- ataxia syndrome. Curr Opin Pediatr 22(6):745–750. https://doi.org/10.1097/MOP.0b013e32833fde3f
doi: 10.1097/MOP.0b013e32833fde3f
pubmed: 20871403
Bataller L, Graus F, Saiz A, Vilchez JJ (2001) Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 124:437–43. https://doi.org/10.1093/brain/124.2.437
doi: 10.1093/brain/124.2.437
pubmed: 11157570
Pranzatelli MR, Tate ED, McGee NR (2017) Demographic, clinical, and immunologic features of 389 children with opsoclonus-myoclonus syndrome: a cross-sectional study. Front Neurol 8:468. https://doi.org/10.3389/fneur.2017.00468
doi: 10.3389/fneur.2017.00468
pubmed: 28959231
pmcid: 5604058
Pittock SJ, Lucchinetti CF, Lennon VA (2003) Anti-neuronal nuclear autoantibody type 2: Paraneoplastic accompaniments. Ann Neurol 53:580–7. https://doi.org/10.1002/ana.10518
doi: 10.1002/ana.10518
pubmed: 12730991
Oh SY, Kim JS, Dieterich M (2019) Update on opsoclonus–myoclonus syndrome in adults. J Neurol 266(6):1541–1548. https://doi.org/10.1007/s00415-018-9138-7
doi: 10.1007/s00415-018-9138-7
pubmed: 30483882
Camdessanché JP, Antoine JC, Honnorat J, et al (2002) Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain 125:. https://doi.org/10.1093/brain/awf006
Molinuevo JL, Graus F, Serrano C et al (1998) Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Ann Neurol 44:976–80. https://doi.org/10.1002/ana.410440620
doi: 10.1002/ana.410440620
pubmed: 9851446
Antoine JC, Camdessanché JP (2017) Paraneoplastic neuropathies. Curr Opin Neurol 30:513–520. https://doi.org/10.1097/WCO.0000000000000475
doi: 10.1097/WCO.0000000000000475
pubmed: 28682959
Dubey D, Jitprapaikulsan J, Bi H et al (2019) Amphiphysin-IgG autoimmune neuropathy: a recognizable clinicopathologic syndrome. Neurology 93:e1873–e1880. https://doi.org/10.1212/WNL.0000000000008472
doi: 10.1212/WNL.0000000000008472
pubmed: 31624089
Lee H-R, Lennon VA, Camilleri M, Prather CM (2001) Paraneoplastic gastrointestinal motor dysfunction: clinical and laboratory characteristics. Am J Gastroenterol 96:373–9. https://doi.org/10.1111/j.1572-0241.2001.03454.x
doi: 10.1111/j.1572-0241.2001.03454.x
pubmed: 11232678
Koike H, Sobue G (2013) Paraneoplastic neuropathy. Handb Clin Neurol 115:713–726. https://doi.org/10.1016/B978-0-444-52902-2.00041-2
doi: 10.1016/B978-0-444-52902-2.00041-2
pubmed: 23931811
O’neill JH, Murray NMF, Newsom-davis J (1988) The lambert-eaton myasthenic syndrome: A REVIEW of 50 cases. Brain 111:577–96. https://doi.org/10.1093/brain/111.3.577
doi: 10.1093/brain/111.3.577
pubmed: 2838124
Schoser B, Eymard B, Datt J, Mantegazza R (2017) Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer. J Neurol 264(9):1854–1863. https://doi.org/10.1007/s00415-017-8541-9
doi: 10.1007/s00415-017-8541-9
pubmed: 28608304
Motomura M, Lang B, Johnston I et al (1997) Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci 147:35–42. https://doi.org/10.1016/S0022-510X(96)05303-8
doi: 10.1016/S0022-510X(96)05303-8
pubmed: 9094058
Pittock SJ, Parisi JE, McKeon A et al (2010) Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri). Arch Neurol 67:1109–15. https://doi.org/10.1001/archneurol.2010.209
doi: 10.1001/archneurol.2010.209
pubmed: 20837856
Mandel-Brehm C, Dubey D, Kryzer TJ, et al (2019) Kelch-like protein 11 antibodies in seminoma-associated paraneoplastic encephalitis. N Engl J Med 381. https://doi.org/10.1056/nejmoa1816721
Dubey D, Wilson MR, Clarkson B et al (2020) Expanded clinical phenotype, oncological associations, and immunopathologic insights of paraneoplastic kelch-like protein-11 encephalitis. JAMA Neurol 77:1420–1429. https://doi.org/10.1001/jamaneurol.2020.2231
doi: 10.1001/jamaneurol.2020.2231
pubmed: 32744608
Torres-Vega E, Mancheño N, Cebrián-Silla A et al (2017) Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis. Neurology 88:1235–1242. https://doi.org/10.1212/WNL.0000000000003778
doi: 10.1212/WNL.0000000000003778
pubmed: 28251919
pmcid: 5373776
Irani SR, Pettingill P, Kleopa KA et al (2012) Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol 72:241–55. https://doi.org/10.1002/ana.23577
doi: 10.1002/ana.23577
pubmed: 22473710
Forsyth PA, Dalmau J, Graus F et al (1997) Motor neuron syndromes in cancer patients. Ann Neurol 41:722–30. https://doi.org/10.1002/ana.410410608
doi: 10.1002/ana.410410608
pubmed: 9189033
Vogrig A, Joubert B, Maureille A et al (2019) Motor neuron involvement in anti-Ma2-associated paraneoplastic neurological syndrome. J Neurol 266:398–410. https://doi.org/10.1007/s00415-018-9143-x
doi: 10.1007/s00415-018-9143-x
pubmed: 30498914
Dericioglu N, Gocmen R, Tan E (2018) Paraneoplastic striatal encephalitis and myelitis associated with anti-CV2/CRMP-5 antibodies in a patient with small cell lung cancer. Clin Neurol Neurosurg 170:117–119. https://doi.org/10.1016/j.clineuro.2018.05.010
doi: 10.1016/j.clineuro.2018.05.010
pubmed: 29777943
Liu Z, Jiao L, Qiu Z et al (2019) Clinical characteristics of patients with paraneoplastic myelopathy. J Neuroimmunol 330:136–142. https://doi.org/10.1016/j.jneuroim.2019.03.001
doi: 10.1016/j.jneuroim.2019.03.001
pubmed: 30878696
Li K, Zhan Y, Shen X (2020) Multiple intracranial lesions with lung adenocarcinoma: a rare case of MOG-IgG-associated encephalomyelitis. Mult Scler Relat Disord 42:102064. https://doi.org/10.1016/j.msard.2020.102064
doi: 10.1016/j.msard.2020.102064
pubmed: 32234600
Blum P, Jankovic J (1991) Stiff‐person syndrome: an autoimmune disease. Mov Disord 6. https://doi.org/10.1002/mds.870060104
Sarva H, Deik A, Ullah A, Severt WL (2016) Clinical spectrum of stiff person syndrome: a review of recent reports. Tremor and Other Hyperkinetic Movements 6:340. https://doi.org/10.7916/D85M65GD
doi: 10.7916/D85M65GD
pubmed: 26989571
pmcid: 4790195
Pittock SJ, Lucchinetti CF, Parisi JE et al (2005) Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 58:96–107. https://doi.org/10.1002/ana.20529
doi: 10.1002/ana.20529
pubmed: 15984030
Tobin WO, Lennon VA, Komorowski L et al (2014) DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology 83:1797–803. https://doi.org/10.1212/WNL.0000000000000991
doi: 10.1212/WNL.0000000000000991
pubmed: 25320100
pmcid: 4240433
Shah S, Vazquez Do Campo R, Kumar N et al (2021) Paraneoplastic myeloneuropathies: clinical, oncologic, and serologic accompaniments. Neurology 96:e632. https://doi.org/10.1212/WNL.0000000000011218
doi: 10.1212/WNL.0000000000011218
pubmed: 33208548
pmcid: 7905784
Titulaer MJ, Soffietti R, Dalmau J et al (2011) Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force. Eur J Neurol 18:19-e3. https://doi.org/10.1111/j.1468-1331.2010.03220.x
doi: 10.1111/j.1468-1331.2010.03220.x
pubmed: 20880069
Keime-Guibert F, Graus F, Fleury A et al (2000) Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (anti-Hu, Anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 68:479–82. https://doi.org/10.1136/jnnp.68.4.479
doi: 10.1136/jnnp.68.4.479
pubmed: 10727484
pmcid: 1736897
Berzero G, Karantoni E, Dehais C et al (2018) Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies. J Neurol Neurosurg Psychiatry 89(7):789–792. https://doi.org/10.1136/jnnp-2017-316904
doi: 10.1136/jnnp-2017-316904
pubmed: 29084869
McKeon A (2016) Autoimmune encephalopathies and dementias. Contin Lifelong Learn Neurol 22(2 Dementia):538–58. https://doi.org/10.1212/CON.0000000000000299
doi: 10.1212/CON.0000000000000299
Vernino S, O’Neill BP, Marks RS et al (2004) Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro Oncol 6:55–62. https://doi.org/10.1215/S1152851703000395
doi: 10.1215/S1152851703000395
pubmed: 14769141
pmcid: 1871966
Bell J, Moran C, Blatt J (2008) Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus. Pediatr Blood Cancer 50:370–1. https://doi.org/10.1002/pbc.20899
doi: 10.1002/pbc.20899
pubmed: 16652344
Russo C, Cohn SL, Petruzzi MJ, De Alarcon PA (1997) Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol 28:284–8. https://doi.org/10.1002/(SICI)1096-911X(199704)28:4%3c284::AID-MPO7%3e3.0.CO;2-E
doi: 10.1002/(SICI)1096-911X(199704)28:4<284::AID-MPO7>3.0.CO;2-E
pubmed: 9078325
Mantegazza R, Meisel A, Sieb JP et al (2015) The European LEMS Registry: baseline demographics and treatment approaches. Neurol Ther 4:105–24. https://doi.org/10.1007/s40120-015-0034-0
doi: 10.1007/s40120-015-0034-0
pubmed: 26525537
pmcid: 4685864
Rojas I, Graus F, Keime-Guibert F et al (2000) Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 55:713–5. https://doi.org/10.1212/WNL.55.5.713
doi: 10.1212/WNL.55.5.713
pubmed: 10980743
Chinn JS, Schuffler MD (1988) Paraneoplastic visceral neuropathy as a cause of severe gastrointestinal motor dysfunction. Gastroenterology 95:1279–86. https://doi.org/10.1016/0016-5085(88)90362-9
doi: 10.1016/0016-5085(88)90362-9
pubmed: 2844621
Kruger S, Ilmer M, Kobold S et al (2019) Advances in cancer immunotherapy 2019 - latest trends. J Exp Clin Cancer Res 38:268. https://doi.org/10.1186/s13046-019-1266-0
doi: 10.1186/s13046-019-1266-0
pubmed: 31217020
pmcid: 6585101
Dalakas MC (2018) Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system. Ther Adv Neurol Disord 11:1756286418799864. https://doi.org/10.1177/1756286418799864
doi: 10.1177/1756286418799864
pubmed: 30245744
pmcid: 6144585
Dubey D, David WS, Reynolds KL et al (2020) Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol 87:659–669. https://doi.org/10.1002/ana.25708
doi: 10.1002/ana.25708
pubmed: 32086972
Johnson DB, Manouchehri A, Haugh AM et al (2019) Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer 7:134. https://doi.org/10.1186/s40425-019-0617-x
doi: 10.1016/j.ejca.2016.12.001
pubmed: 28064139
Johnson DB, Manouchehri A, Haugh AM et al (2019) Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer 7:134. https://doi.org/10.1186/s40425-019-0617-x
doi: 10.1186/s40425-019-0617-x
pubmed: 31118078
pmcid: 6530194
Guidon AC, Burton LB, Chwalisz BK et al (2021) Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer 9. https://doi.org/10.1136/jitc-2021-002890
Chompoopong P, Zekeridou A, Shelly S et al (2022) Comparison of immune checkpoint inhibitor-related neuropathies among patients with neuroendocrine and non-neuroendocrine tumours. J Neurol Neurosurg Psychiatry 93:112–114. https://doi.org/10.1136/JNNP-2021-326369
doi: 10.1136/JNNP-2021-326369
pubmed: 34039631
Sechi E, Markovic SN, McKeon A, Dubey D, Liewluck T, Lennon VA, Lopez-Chiriboga AS, Klein CJ, Mauermann M, Pittock SJ, Flanagan EPZA (2020) Neurologic autoimmunity and immune checkpoint inhibitors autoantibody profiles and outcomes. Mayo Clin. https://doi.org/10.1212/WNL.0000000000010632
doi: 10.1212/WNL.0000000000010632
Gkiozos I, Kopitopoulou A, Kalkanis A et al (2018) Sarcoidosis-like reactions induced by checkpoint inhibitors. J Thorac Oncol 13:1076–1082. https://doi.org/10.1016/J.JTHO.2018.04.031
doi: 10.1016/J.JTHO.2018.04.031
pubmed: 29763666
Graus F (2019) Dalmau J (2019) Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol 169(16):535–548. https://doi.org/10.1038/s41571-019-0194-4
doi: 10.1038/s41571-019-0194-4
Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158–168. https://doi.org/10.1056/NEJMRA1703481/SUPPL_FILE/NEJMRA1703481_DISCLOSURES.PDF
doi: 10.1056/NEJMRA1703481/SUPPL_FILE/NEJMRA1703481_DISCLOSURES.PDF
pubmed: 29320654
Fellner A, Makranz C, Lotem M et al (2018) Neurologic complications of immune checkpoint inhibitors. J Neurooncol 137:601–609. https://doi.org/10.1007/S11060-018-2752-5
doi: 10.1007/S11060-018-2752-5
pubmed: 29332184
Papadopoulos KP, Romero RS, Gonzalez G, et al Anti-Hu-associated autoimmune limbic encephalitis in a patient with PD-1 inhibitor-responsive myxoid chondrosarcoma. https://doi.org/10.1634/theoncologist.2017-0344
Williams TJ, Benavides DR, Patrice KA et al (2016) Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 73:928–933. https://doi.org/10.1001/JAMANEUROL.2016.1399
doi: 10.1001/JAMANEUROL.2016.1399
pubmed: 27271951
Graus F, Dalmau J (2019) Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol 16(9):535–548. https://doi.org/10.1038/s41571-019-0194-4
doi: 10.1038/s41571-019-0194-4
pubmed: 30867573
Vogrig A, Fouret M, Joubert B et al (2019) Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. Neurol Neuroimmunol NeuroInflammation 6:e604. https://doi.org/10.1212/NXI.0000000000000604
doi: 10.1212/NXI.0000000000000604
Kawamura R, Nagata E, Mukai M et al (2017) Acute cerebellar ataxia induced by nivolumab. Intern Med 56:3357–3359. https://doi.org/10.2169/internalmedicine.8895-17
doi: 10.2169/internalmedicine.8895-17
pubmed: 29249765
pmcid: 5790727
Maller B, Peguero E, Tanvetyanon T (2018) Ipilimumab/nivolumab-related opsoclonus-myoclonus-ataxia syndrome variant in a patient with malignant pleural mesothelioma. J Immunother 41:411–412. https://doi.org/10.1097/CJI.0000000000000228
doi: 10.1097/CJI.0000000000000228
pubmed: 29742520
Matsuoka H, Kimura H, Koba H et al (2018) Nivolumab-induced limbic encephalitis with Anti-Hu antibody in a patient with advanced pleomorphic carcinoma of the lung. Clin Lung Cancer 19:e597–e599. https://doi.org/10.1016/J.CLLC.2018.04.009
doi: 10.1016/J.CLLC.2018.04.009
pubmed: 29857970
Kunchok A, Zekeridou A, Pittock S (2020) CRMP5-IgG–associated paraneoplastic myelopathy with PD-L1 inhibitor therapy. JAMA Neurol 77:255–256. https://doi.org/10.1001/JAMANEUROL.2019.4379
doi: 10.1001/JAMANEUROL.2019.4379
pubmed: 31860013
Puwanant A, Isfort M, Lacomis D, Živković SA (2019) Clinical spectrum of neuromuscular complications after immune checkpoint inhibition. Neuromuscul Disord 29:127–133. https://doi.org/10.1016/J.NMD.2018.11.012
doi: 10.1016/J.NMD.2018.11.012
pubmed: 30638612
Puwanant A, Isfort M, Lacomis D, Živković SA (2019) Clinical spectrum of neuromuscular complications after immune checkpoint inhibition. Neuromuscul Disord 29(2):127–133. https://doi.org/10.1016/j.nmd.2018.11.012
doi: 10.1016/j.nmd.2018.11.012
pubmed: 30638612
Agrawal K, Agrawal N (2019) Lambert-Eaton myasthenic syndrome secondary to nivolumab and ipilimumab in a patient with small-cell lung cancer. https://doi.org/10.1155/2019/5353202
Nakatani Y, Tanaka N, Enami T et al (2018) Lambert-Eaton myasthenic syndrome caused by nivolumab in a patient with squamous cell lung cancer. Case Rep Neurol 10:346. https://doi.org/10.1159/000494078
doi: 10.1159/000494078
pubmed: 30627102
pmcid: 6323386
Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1714. https://doi.org/10.1200/JCO.2017.77.6385
doi: 10.1200/JCO.2017.77.6385
pubmed: 29442540
Puzanov I, Diab A, Abdallah K et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group Equal contributors. J Immunother Cancer 5:95. https://doi.org/10.1186/s40425-017-0300-z
doi: 10.1186/s40425-017-0300-z
pubmed: 29162153
pmcid: 5697162